1st Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$480,425
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY12 Presidential Budget Request, FY12 and FY13 Budget H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Congressional Budget Office (CBO); Commerce, Dept of (DOC); SENATE; Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); White House Office; Office of Management & Budget (OMB)

Bills named: H.R. 3988 (112th)

Trade (domestic/foreign) TRD

Free Trade Agreements-Trans Pacific Partnership, Korean Free Trade Agreement, Anti-Counterfeiting Trade Agreement (ACTA), Generic medicines

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS —

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); White House Office; SENATE; Patent & Trademark Office (PTO); Federal Trade Commission (FTC); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3497 - MODDERN Cures Act of 2011 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 S.27 Preserve Access to Affordable Generics Act S.373 Fair Prescription Drug Competition Act S.1734 - Generating Antibiotic Incentives Now Act of 2011 S. 1882 - The Fair and Immediate Release of Generic Drugs Act

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS —

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); SENATE; Office of Management & Budget (OMB); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); White House Office; Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3995 (112th), S. 27 (112th), S. 373 (112th), S. 1882 (112th), S. 1734 (112th), H.R. 3988 (112th), H.R. 3497 (112th), H.R. 4332 (112th), H.R. 2182 (112th)

Medicare/Medicaid MMM

FY 2012 Budget, Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Average Manufacture Price (AMP)/AMP Publication, and generic drugs S.44 Medicare Prescription Drug Negotiation Act S.1356 - Affordable Medicines Utilization Act of 2011 H.R.3342 - Affordable Medicines Utilization Act of 2011

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS —

Contacted: White House Office; Commerce, Dept of (DOC); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Federal Trade Commission (FTC); SENATE; Patent & Trademark Office (PTO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES

Bills named: S. 1356 (112th), S. 44 (112th), H.R. 3342 (112th)

Pharmacy PHA

FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, and generic drugs Bills: H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R.3839 - Drug Shortage Prevention Act of 2012 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 S.44 Medicare Prescription Drug Negotiation Act S.296 and H.R.2245 Preserving Access to Life-Saving Medication Act S.373 Fair Prescription Drug Competition Act S.1584 - Drug Safety and Accountability Act of 2011 S.1734 - Generating Antibiotic Incentives Now Act of 2011

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JAMES M FENTON —
MARK D HENDRICKSON —
JASON R MONEY —
RALPH NEAS —

Contacted: Commerce, Dept of (DOC); SENATE; Federal Trade Commission (FTC); White House Office; Office of Management & Budget (OMB); Congressional Budget Office (CBO); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES

Bills named: S. 44 (112th), H.R. 3026 (112th), S. 373 (112th), H.R. 3839 (112th), H.R. 4332 (112th), H.R. 2182 (112th), S. 1584 (112th), S. 1734 (112th), H.R. 3995 (112th), S. 296 (112th), H.R. 3988 (112th), H.R. 2245 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.